ALS drug trial halted: safety study of VRG50635 ends early
NCT ID NCT06215755
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tested a new drug called VRG50635 in 54 adults with ALS to see if it is safe and tolerable. Participants received multiple doses of the drug, and researchers monitored side effects and disease progression. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Helsinki University Hospital
Helsinki, Uusimaa, FI-00029, Finland
-
Stan Cassidy Centre for Rehabilitation (Horizon NB)
Montreal, Quebec, H3A 2B4, Canada
-
The Neuro - Montréal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada
-
Turku University Hospital
Turku, Western Finland, FI-20520, Finland
-
UZ Leuven
Leuven, Flemish Brabant, Belgium
-
University Medical Center Utrecht
Utrecht, 3584 CX, Netherlands
-
University of Eastern Finland, Brain Research Unit
Kuopio, Eastern Finland, FI-70210, Finland
Conditions
Explore the condition pages connected to this study.